PYC Therapeutics (ASX:PYC) has achieved notable progress in its Phase 1a Single Ascending Dose clinical trial for its RNA-based therapeutic candidate, PYC-003, targeting autosomal dominant polycystic kidney disease. …
PYC Therapeutics accelerates clinical progress of PYC-003 in PKD trial
August 10, 2025 Australian Biotech
Latest Video
New Stories
-
Could the realities of AI quickly date or even swamp the HTA Review outcomes?
August 11, 2025 - - Latest News -
We asked ChatGPT to produce a podcast script explaining the pros and cons of the HTA Review
August 10, 2025 - - Latest News -
PYC Therapeutics accelerates clinical progress of PYC-003 in PKD trial
August 10, 2025 - - Australian Biotech -
Neuren expands NNZ-2591 pipeline to include SYNGAP1-related disorder
August 10, 2025 - - Australian Biotech -
AI has to be seen as a generational opportunity to get medicines to patients faster
August 10, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 8 August
August 8, 2025 - - Podcast -
Historic research grant program aims to halve breast cancer deaths
August 8, 2025 - - Latest News